Combined treatment with vitamin C and methotrexate inhibits triple-negative breast cancer cell growth by increasing H2O2 accumulation and activating caspase-3 and p38 pathways
- Authors:
- Ching-Wen Wu
- Hsiao-Chun Liu
- Yung-Luen Yu
- Yu-Ting Hung
- Chyou-Wei Wei
- Giou-Teng Yiang
-
Affiliations: Department of Cardiac Surgery, Tungs' Taichung Metroharbor Hospital, Taichung 435, Taiwan, R.O.C., Department of Nursing, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei 231, Taiwan, R.O.C., Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan, R.O.C., Department of Nutrition, Master Program of Biomedical Nutrition, Hungkuang University, Taichung 433, Taiwan, R.O.C., Department of Emergency Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei 231, Taiwan, R.O.C. - Published online on: February 10, 2017 https://doi.org/10.3892/or.2017.5439
- Pages: 2177-2184
This article is mentioned in:
Abstract
Yu YL, Chou RH, Liang JH, Chang WJ, Su KJ, Tseng YJ, Huang WC, Wang SC and Hung MC: Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides. PLoS One. 8:e613622013. View Article : Google Scholar : PubMed/NCBI | |
Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, et al: Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 30:1879–1787. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ojo D, Wei F, Liu Y, Wang E, Zhang H, Lin X, Wong N, Bane A and Tang D: Factors promoting tamoxifen resistance in breast cancer via stimulating breast cancer stem cell expansion. Curr Med Chem. 22:2360–2374. 2015. View Article : Google Scholar : PubMed/NCBI | |
Spring L, Bardia A and Modi S: Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: Rationale, current status, and future directions. Discov Med. 21:65–74. 2016.PubMed/NCBI | |
Lumachi F, Chiara GB, Foltran L and Basso SM: Proteomics as a guide for personalized adjuvant chemotherapy in patients with early breast cancer. Cancer Genomics Proteomics. 12:385–390. 2015.PubMed/NCBI | |
Williams CB, Soloff AC, Ethier SP and Yeh ES: Perspectives on epidermal growth factor receptor regulation in triple-negative breast cancer: Ligand-mediated mechanisms of receptor regulation and potential for clinical targeting. Adv Cancer Res. 127:253–281. 2015. View Article : Google Scholar : PubMed/NCBI | |
Hudis CA and Gianni L: Triple-negative breast cancer: An unmet medical need. Oncologist. 16:(Suppl 1). 1–11. 2011. View Article : Google Scholar : PubMed/NCBI | |
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI | |
Schofield RC, Ramanathan LV, Murata K, Fleisher M, Pessin MS and Carlow DC: Development of an assay for methotrexate and its metabolites 7-hydroxy methotrexate and DAMPA in serum by LC-MS/MS. Methods Mol Biol. 1383:213–222. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hara A, Taguchi A, Aoki H, Hatano Y, Niwa M, Yamada Y and Kunisada T: Folate antagonist, methotrexate induces neuronal differentiation of human embryonic stem cells transplanted into nude mouse retina. Neurosci Lett. 477:138–143. 2010. View Article : Google Scholar : PubMed/NCBI | |
Pavy S, Constantin A, Pham T, Gossec L, Maillefert JF, Cantagrel A, Combe B, Flipo RM, Goupille P, Le Loët X, et al: Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 73:388–395. 2006. View Article : Google Scholar : PubMed/NCBI | |
Whittle SL and Hughes RA: Folate supplementation and methotrexate treatment in rheumatoid arthritis: A review. Rheumatology (Oxford). 43:267–271. 2004. View Article : Google Scholar : PubMed/NCBI | |
Cho KM, Kim YJ, Kim SH, Kim JW, Lee JO, Han JH, Lee KW, Kim JH, Kim CY, Bang SM, et al: Salvage treatment with intracerebrospinal fluid thiotepa in patients with leptomeningeal metastasis after failure of methotrexate-based treatment. Anticancer Res. 35:5631–5638. 2015.PubMed/NCBI | |
van der Plas E, Nieman BJ, Butcher DT, Hitzler JK, Weksberg R, Ito S and Schachar R: Neurocognitive late effects of chemotherapy in survivors of acute lymphoblastic leukemia: Focus on methotrexate. J Can Acad Child Adolesc Psychiatry. 24:25–32. 2015.PubMed/NCBI | |
Yiang GT, Chou PL, Hung YT, Chen JN, Chang WJ, Yu YL and Wei CW: Vitamin C enhances anticancer activity in methotrexate-treated Hep3B hepatocellular carcinoma cells. Oncol Rep. 32:1057–1063. 2014.PubMed/NCBI | |
Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A, et al: Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 43:972–980. 2013. View Article : Google Scholar : PubMed/NCBI | |
Takemura Y and Jackman AL: Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Anticancer Drugs. 8:3–16. 1997. View Article : Google Scholar : PubMed/NCBI | |
Fukuda T, Tanabe M, Kobayashi K, Fukada I, Takahashi S, Iwase T and Ito Y: Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine. Springerplus. 4:3762015. View Article : Google Scholar : PubMed/NCBI | |
Leone JP, Leone J, Vallejo CT, Pérez JE, Romero AO, Machiavelli MR, Romero Acuña L, Domínguez ME, Langui M, Fasce HM, et al: Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience. Breast Cancer Res Treat. 143:313–323. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wu CE, Chen SC, Lin YC, Lo YF, Hsueh S and Chang HK: Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy. Anticancer Res. 34:1301–1306. 2014.PubMed/NCBI | |
Shea B, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T, Bombardier C, Wells GA and Tugwell P: Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 41:1049–1060. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lee HJ, Hong SK, Seo JK, Lee D and Sung HS: A case of cutaneous side effect of methotrexate mimicking Behçets disease. Ann Dermatol. 23:412–414. 2011. View Article : Google Scholar : PubMed/NCBI | |
Colomer Gallardo A, Martínez Rodríguez R, Castillo Pacheco C, González Satue C and Ibarz Servio L: Dermatological side effects of intravesical mitomycin C: Delayed hypersensitivity. Arch Esp Urol. 69:89–91. 2016.PubMed/NCBI | |
Elazzazy S, Mohamed AE and Gulied A: Cyclophosphamide-induced symptomatic hyponatremia, a rare but severe side effect: A case report. Onco Targets Ther. 7:1641–1645. 2014. View Article : Google Scholar : PubMed/NCBI | |
Sun W, Yan C, Jia S and Hu J: Correlation analysis of peripheral DPYD gene polymorphism with 5-fluorouracil susceptibility and side effects in colon cancer patients. Int J Clin Exp Med. 7:5857–5861. 2014.PubMed/NCBI | |
Rietjens IM, Boersma MG, Haan L, Spenkelink B, Awad HM, Cnubben NH, van Zanden JJ, Woude H, Alink GM and Koeman JH: The pro-oxidant chemistry of the natural antioxidants vitamin C, vitamin E, carotenoids and flavonoids. Environ Toxicol Pharmacol. 11:321–333. 2002. View Article : Google Scholar : PubMed/NCBI | |
Mason SA, Gatta PA Della, Snow RJ, Russell AP and Wadley GD: Ascorbic acid supplementation improves skeletal muscle oxidative stress and insulin sensitivity in people with type 2 diabetes: Findings of a randomized controlled study. Free Radic Biol Med. 93:227–238. 2016. View Article : Google Scholar : PubMed/NCBI | |
Lee WJ: The prospects of vitamin C in cancer therapy. Immune Netw. 9:147–152. 2009. View Article : Google Scholar : PubMed/NCBI | |
Nagappan A, Park KI, Park HS, Kim JA, Hong GE, Kang SR, Lee DH, Kim EH, Lee WS, Won CK, et al: Vitamin C induces apoptosis in AGS cells by down-regulation of 14-3-3σ via a mitochondrial dependent pathway. Food Chem. 135:1920–1928. 2012. View Article : Google Scholar : PubMed/NCBI | |
Guerriero E, Sorice A, Capone F, Napolitano V, Colonna G, Storti G, Castello G and Costantini S: Vitamin C effect on mitoxantrone-induced cytotoxicity in human breast cancer cell lines. PLoS One. 9:e1152872014. View Article : Google Scholar : PubMed/NCBI | |
Vetvicka V and Vetvickova J: Combination of glucan, resveratrol and vitamin C demonstrates strong anti-tumor potential. Anticancer Res. 32:81–87. 2012.PubMed/NCBI | |
Nagao T, Warnakulasuriya S, Nakamura T, Kato S, Yamamoto K, Fukano H, Suzuki K, Shimozato K and Hashimoto S: Treatment of oral leukoplakia with a low-dose of beta-carotene and vitamin C supplements: A randomized controlled trial. Int J Cancer. 136:1708–1717. 2015. View Article : Google Scholar : PubMed/NCBI | |
Tokarski S, Rutkowski M, Godala M, Mejer A and Kowalski J: The impact of ascorbic acid on the concentrations of antioxidative vitamins in the plasma of patients with non-small cell lung cancer undergoing first-line chemotherapy. Pol Merkur Lekarski. 35:136–140. 2013.(In Polish). PubMed/NCBI | |
Nechuta S, Lu W, Chen Z, Zheng Y, Gu K, Cai H, Zheng W and Shu XO: Vitamin supplement use during breast cancer treatment and survival: A prospective cohort study. Cancer Epidemiol Biomarkers Prev. 20:262–271. 2011. View Article : Google Scholar : PubMed/NCBI | |
Subramani T, Yeap SK, Ho WY, Ho CL, Omar AR, Aziz SA, Rahman NM and Alitheen NB: Vitamin C suppresses cell death in MCF-7 human breast cancer cells induced by tamoxifen. J Cell Mol Med. 18:305–313. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hong SW, Jin DH, Hahm ES, Yim SH, Lim JS, Kim KI, Yang Y, Lee SS, Kang JS, Lee WJ, et al: Ascorbate (vitamin C) induces cell death through the apoptosis-inducing factor in human breast cancer cells. Oncol Rep. 18:811–815. 2007.PubMed/NCBI | |
Uetaki M, Tabata S, Nakasuka F, Soga T and Tomita M: Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress. Sci Rep. 5:138962015. View Article : Google Scholar : PubMed/NCBI | |
van der Reest J and Gottlieb E: Anti-cancer effects of vitamin C revisited. Cell Res. 26:269–270. 2016. View Article : Google Scholar : PubMed/NCBI | |
Mense SM, Singh B, Remotti F, Liu X and Bhat HK: Vitamin C and alpha-naphthoflavone prevent estrogen-induced mammary tumors and decrease oxidative stress in female ACI rats. Carcinogenesis. 30:1202–1208. 2009. View Article : Google Scholar : PubMed/NCBI | |
Yiang GT, Yu YL, Lin KT, Chen JN, Chang WJ and Wei CW: Acetaminophen induces JNK/p38 signaling and activates the caspase-9-3-dependent cell death pathway in human mesenchymal stem cells. Int J Mol Med. 36:485–492. 2015.PubMed/NCBI | |
Yu YL, Yiang GT, Chou PL, Tseng HH, Wu TK, Hung YT, Lin PS, Lin SY, Liu HC, Chang WJ, et al: Dual role of acetaminophen in promoting hepatoma cell apoptosis and kidney fibroblast proliferation. Mol Med Rep. 9:2077–2084. 2014.PubMed/NCBI | |
Lin BR, Yu CJ, Chen WC, Lee HS, Chang HM, Lee YC, Chien CT and Chen CF: Green tea extract supplement reduces D-galactosamine-induced acute liver injury by inhibition of apoptotic and proinflammatory signaling. J Biomed Sci. 16:352009. View Article : Google Scholar : PubMed/NCBI | |
Kolli VK, Abraham P, Isaac B and Selvakumar D: Neutrophil infiltration and oxidative stress may play a critical role in methotrexate-induced renal damage. Chemotherapy. 55:83–90. 2009. View Article : Google Scholar : PubMed/NCBI | |
Ohgidani M, Komizu Y, Goto K and Ueoka R: Residual powders from Shochu distillation remnants induce apoptosis in human hepatoma cells via the caspase-independent pathway. J Biosci Bioeng. 114:104–109. 2012. View Article : Google Scholar : PubMed/NCBI | |
Yu VW and Ho WS: Tetrandrine inhibits hepatocellular carcinoma cell growth through the caspase pathway and G2/M phase. Oncol Rep. 29:2205–2210. 2013.PubMed/NCBI | |
Wu Y, van der Schaft DW, Baaijens FP and Oomens CW: Cell death induced by mechanical compression on engineered muscle results from a gradual physiological mechanism. J Biomech. 49:1071–1077. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chen J, Li Y, Hao H, Li C, Du Y, Hu Y, Li J, Liang Z, Li C, Liu J, et al: Mesenchymal stem cell conditioned medium promotes proliferation and migration of alveolar epithelial cells under Septic conditions in vitro via the JNK-P38 signaling pathway. Cell Physiol Biochem. 37:1830–1846. 2015. View Article : Google Scholar : PubMed/NCBI | |
Lee K, Chung YH, Ahn H, Kim H, Rho J and Jeong D: Selective regulation of MAPK signaling mediates RANKL-dependent osteoclast differentiation. Int J Biol Sci. 12:235–245. 2016. View Article : Google Scholar : PubMed/NCBI | |
Tan CS, Gilligan D and Pacey S: Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 16:e447–e459. 2015. View Article : Google Scholar : PubMed/NCBI | |
Sato F, Kubota Y, Natsuizaka M, Maehara O, Hatanaka Y, Marukawa K, Terashita K, Suda G, Ohnishi S, Shimizu Y, et al: EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition. Cancer Biol Ther. 16:933–940. 2015. View Article : Google Scholar : PubMed/NCBI | |
Li X, Qin N, Wang J, Yang X, Zhang X, Lv J, Wu Y, Zhang H, Nong J and Zhang Q: Clinical observation of icotinib hydrochloride for advanced non-small cell lung cancer patients with EGFR status identified. Zhongguo Fei Ai Za Zhi. 18:734–739. 2015.(In Chinese). PubMed/NCBI | |
Osarogiagbon RU, Cappuzzo F, Ciuleanu T, Leon L and Klughammer B: Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: Results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. Transl Lung Cancer Res. 4:465–474. 2015.PubMed/NCBI | |
Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G, Viale G, Veronesi P, Luini A, Intra M, et al: Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: Clinical and biological activity. Clin Breast Cancer. 12:207–214. 2012. View Article : Google Scholar : PubMed/NCBI | |
Tolcher AW, LoRusso P, Arzt J, Busman TA, Lian G, Rudersdorf NS, Vanderwal CA, Kirschbrown W, Holen KD and Rosen LS: Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 76:1025–1032. 2015. View Article : Google Scholar : PubMed/NCBI | |
Evans MK, Tovmasyan A, Batinic-Haberle I and Devi GR: Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death. Free Radic Biol Med. 68:302–314. 2014. View Article : Google Scholar : PubMed/NCBI | |
Ohtani S, Iwamaru A, Deng W, Ueda K, Wu G, Jayachandran G, Kondo S, Atkinson EN, Minna JD, Roth JA, et al: Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy. Cancer Res. 67:6293–6303. 2007. View Article : Google Scholar : PubMed/NCBI | |
Lin SY, Lai WW, Chou CC, Kuo HM, Li TM, Chung JG and Yang JH: Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A375.S2 cells. Melanoma Res. 16:509–519. 2006. View Article : Google Scholar : PubMed/NCBI | |
Nagao N, Nakayama T, Etoh T, Saiki I and Miwa N: Tumor invasion is inhibited by phosphorylated ascorbate via enrichment of intracellular vitamin C and decreasing of oxidative stress. J Cancer Res Clin Oncol. 126:511–518. 2000. View Article : Google Scholar : PubMed/NCBI | |
Liu JW, Nagao N, Kageyama K and Miwa N: Antimetastatic and anti-invasive ability of phospho-ascorbyl palmitate through intracellular ascorbate enrichment and the resultant antioxidant action. Oncol Res. 11:479–487. 1999.PubMed/NCBI | |
Pires AS, Marques CR, Encarnação JC, Abrantes AM, Mamede AC, Laranjo M, Gonçalves AC, Sarmento-Ribeiro AB and Botelho MF: Ascorbic acid and colon cancer: An oxidative stimulus to cell death depending on cell profile. Eur J Cell Biol. 95:208–218. 2016. View Article : Google Scholar : PubMed/NCBI | |
Beck R, Pedrosa RC, Dejeans N, Glorieux C, Levêque P, Gallez B, Taper H, Eeckhoudt S, Knoops L, Calderon PB, et al: Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study. Invest New Drugs. 29:891–900. 2011. View Article : Google Scholar : PubMed/NCBI | |
Venturelli S, Sinnberg TW, Berger A, Noor S, Levesque MP, Böcker A, Niessner H, Lauer UM, Bitzer M, Garbe C, et al: Epigenetic impacts of ascorbate on human metastatic melanoma cells. Front Oncol. 4:2272014. View Article : Google Scholar : PubMed/NCBI | |
Ma Y, Chapman J, Levine M, Polireddy K, Drisko J and Chen Q: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 6:222ra182014. View Article : Google Scholar : PubMed/NCBI | |
Cieslak JA and Cullen JJ: Treatment of pancreatic cancer with pharmacological ascorbate. Curr Pharm Biotechnol. 16:759–770. 2015. View Article : Google Scholar : PubMed/NCBI | |
Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G and Ruberti G: MET gene amplification and MET receptor activation are not sufficient to predict efficacy of combined MET and EGFR inhibitors in EGFR TKI-resistant NSCLC cells. PLoS One. 10:e01433332015. View Article : Google Scholar : PubMed/NCBI | |
De S, Dermawan JK and Stark GR: EGF receptor uses SOS1 to drive constitutive activation of NF-κB in cancer cells. Proc Natl Acad Sci USA. 111:11721–11726. 2014. View Article : Google Scholar : PubMed/NCBI |